Luye Pharma Group Ltd.

2186

BMG570071099

Luye Pharma Group Ltd. is an investment holding company principally engaged in the development, production, marketing and sale of pharmaceutical products. Along with subsidiaries, the Company operates its business through four segments: the Oncology Drugs segment, the Cardiovascular System Drugs segment, the Alimentary Tract and Metabolism Drugs segment and the Others segment. The Companyâs main products include paclitaxe for chemotherapy treatment of cancer, sodium glycididazole for radiotherapy for solid tumours, Chinese medicine for treatment of hypercholesterolaemia, and Rivastigmine Transdermal Patches for treatment of Alzheimerâs disease and dementia, among others. The products are sold under the name of Lipusu, CMNa, Xuezhikang, Maitongna ,and Bei X. Through its subsidiaries, the Company is also engaged in the provision of contract research and process development. The Company operates its business mainly in Mainland China.

Employees

5,270

Sector

Pharmaceuticals

Calendar

25/03/2025 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement and Estimates

More financial data

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

2.695CNY

Average target price

3.275CNY

Spread / Average Target

+21.52%

Consensus

Profit revisions

Estimate revisions

Quarterly earnings, Rate of surprise

Company calendar

Market Closed - Hong Kong S.E. Other stock markets 09:08:11 19/09/2024 BST			5-day change	1st Jan Change
3.020 ^HKD	+2.03%		+3.07%	-19.03%

08-30	Citi Upgrades Luye Pharma to Buy From Sell; Price Target is HK$4	MT
08-28	Luye Pharma Group Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024	CI

Citi Upgrades Luye Pharma to Buy From Sell; Price Target is HK$4	08-30	MT
Luye Pharma Group Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024	08-28	CI
Luye Pharma Group's Subsidiary's Investor Buys 25% Stake in Nanjing Luye for 1 Billion Yuan	08-13	MT
China Approves Luye Pharma's Anti-Psychotic Drug for Trials; Shares Jump 5%	08-06	MT
Luye Pharma Group Ltd. Announces Approval Obtained for Initiating Clinical Trials for Innovative Dual TAAR1/5-HT2CR Agonist	08-05	CI
Luye Pharma Group Gets US FDA Marketing Approval for Schizophrenia Injectable	07-29	MT
Luye Pharma Announces U.S. FDA Approval of ERZOFRI® (Paliperidone Palmitate) Extended-Release Injectable Suspension for Treating Schizophrenia and Schizoaffective Disorder	07-28	CI
Luye Pharma Group to Divest 34.8% Stake in Shenzhen Unit	07-23	MT
Shenzhen Luye Private Equity Investment Fund Partnership (Limited Partnership) managed by Shenzhen Investment Holding Capital Co., Ltd. agreed to acquire 25% stake in Nanjing Luye Pharmaceutical Co., Ltd. from Luye Pharma Group Ltd. for CNY 1.0 billion.	07-22	CI
Chinese Regulator Approves Luye Pharma Group's New Drug for Marketing	07-04	MT
Luye Pharma Group Ltd. Announces Approval of New Analgesic Product Mimeixin (Oxycodone Hydrochloride and Naloxone Hydrochloride Sustained-Release Tablets) for Marketing in China	07-04	CI
Luye Pharma Group Ltd. Announces Manufacturing Facility of Paliperidone Palmitate Extended-Release Injectable Suspension Passed Pai by U.S. FDA with No FDA-483	06-27	CI
Luye Pharma Secures Chinese Medical Regulatory Approval for Parkinson’s Disease Treatment	06-21	MT
Luye Pharma Group Ltd. Announces Its Jinyouping ® (Rotigotine Microspheres for Injection, Ly03003) Developed by the Group Has Been Approved	06-20	CI
China Grants Marketing Approval to Luye Pharma's Anti-Schizophrenia Tablets	06-12	MT
Luye Pharma Group Ltd. Announces Approval of Meibirui (Paliperidone Palmitate Injection) for Marketing in China	06-11	CI
Luye Pharma's Japanese Partner Towa Files New Drug Application for Dementia Patch	06-06	MT
Luye Pharma Group Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	03-27	CI
Luye Pharma Group Announces the Launch of Its Innovative Drug Zepzelca® (Lurbinectedin) for the Treatment of SCLC in Both Hong Kong and Macao	03-07	CI
Luye Enrolls First Patient into Phase III Trial of Anti-Cancer Drug	03-04	MT
Luye Pharma Group Ltd. Announces First Patient Enrolled for Phase 3 Clinical Study of the Group's Innovative Formulation LY01610	03-04	CI
Luye Pharma's Schizophrenia Injectable Surpasses Patent Challenges in US; Shares Fall 3%	02-02	MT
Luye Pharma Group Ltd. Provides Updated Progress in Relation to the Marketing Review of Paliperidone Palmitate Extended-Release Injectable Suspension in the United States	02-01	CI
Luye Pharma Says Two Medications Added to China's National Reimbursement Drug List	12-13	MT
Luye Pharma's Small Cell Lung Cancer Treatment Secures Hong Kong Marketing Approval	12-13	MT

Luye Pharma Group Ltd.

Equities